Native platelet aggregation and response to aspirin in persons with the metabolic syndrome and its components

Metabolic Syndrome and Related Disorders

Volumn 7, Issue 4, 2009, Pages 289-295

  Vaidya, Dhananjay ^a   Yanek, Lisa R ^a   Faraday, Nauder ^a   Moy, Taryn F ^a   Becker, Lewis C ^a   Becker, Diane M ^a  

^a DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; C REACTIVE PROTEIN; CHOLESTEROL; COLLAGEN; FIBRINOGEN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADULT; ARTICLE; ATHEROSCLEROSIS; BODY MASS; CARDIOVASCULAR RISK; CHEMOPROPHYLAXIS; CHOLESTEROL BLOOD LEVEL; CIGARETTE SMOKING; CLINICAL PRACTICE; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DRUG EFFECT; FAMILY HISTORY; FEMALE; FIBRINOGEN BLOOD LEVEL; HIGH RISK PATIENT; HUMAN; HYPERTENSION; IMPAIRED GLUCOSE TOLERANCE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PRACTICE GUIDELINE; PRIORITY JOURNAL; RACE DIFFERENCE; RISK FACTOR; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE AGGREGATION INHIBITION; WAIST CIRCUMFERENCE;

ADULT; ARACHIDONIC ACID; ASPIRIN; COLLAGEN; CORONARY ARTERY DISEASE; FEMALE; GUIDELINES AS TOPIC; HUMANS; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MULTIVARIATE ANALYSIS; PLATELET AGGREGATION; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 68549122673     PISSN: 15404196     EISSN: None     Source Type: Journal    
DOI: 10.1089/met.2008.0083     Document Type: Article

References (19)

1. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC, Jr., Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientifi c Statement. Circulation 2005;112:2735-2752. (Pubitemid 41532612)
2. National Institutes of Health: Third report of the National Cholesterol Education Program Expert Panel on the detection, evaluation and treatment of high blood cholesterol in adults. In. Bethesda, MD. National Institutes of Health; 2001.
3. Golden SH, Folsom AR, Coresh J, Sharrett AR, Szklo M, Brancati F. Risk factor groupings related to insulin resistance and their synergistic effects on subclinical atherosclerosis: the atherosclerosis risk in communities study. Diabetes 2002;51:3069-3076.
4. Sakkinen PA, Wahl P, Cushman M, Lewis MR, Tracy RP. Clustering of procoagulation, infl ammation, and fibrinolysis variables with metabolic factors in insulin resistance syndrome. Am J Epidemiol 2000;152:897-907. (Pubitemid 30840139)
5. Yngen M, Ostenson CG, Hu H, Li N, Hjemdahl P, Wallen NH. Enhanced P-selectin expression and increased soluble CD40 Ligand in patients with Type 1 diabetes mellitus and microangiopathy: evidence for platelet hyperactivity and chronic infl ammation. Diabetologia 2004;47:537-540. (Pubitemid 38491251)
6. Gokulakrishnan K, Deepa R, Mohan V, Gross MD. Soluble P-selectin and CD40L levels in subjects with prediabetes, diabetes mellitus, and metabolic syndrome - the Chennai Urban Rural Epidemiology Study. Metabolism 2006;55:237-242. (Pubitemid 43098993)
7. Becker DM, Segal J, Vaidya D, Yanek LR, Herrera-Galeano JE, Bray PF, Moy TF, Becker LC, Faraday N. Sex differences in platelet reactivity and response to low-dose aspirin therapy. JAMA 2006;295:1420-1427.
8. Hayden M, Pignone M, Phillips C, Mulrow C. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med 2002;136:161-172. (Pubitemid 34073943)
9. Kim MT, Hill MN, Bone LR, Levine DM. Development and testing of the Hill-Bone Compliance to High Blood Pressure Therapy Scale. Prog Cardiovasc Nurs 2000;15:90-96.
10. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jr., Jones DW, Materson BJ, Oparil S, Wright JT, Jr., Roccella EJ. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-1252. (Pubitemid 37553153)
11. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972;18:499-502.
12. Lorenz RL, Hamm CW, Riesner H, Bleifeld W, Weber PC. A prospective study of the diagnostic value of urinary thromboxane in patients presenting with acute chest pain. J Intern Med 1990;227:429-434. (Pubitemid 20192122)
13. Eikelboom JW, Hirsh J, Weitz JI, Johnston M, Yi Q, Yusuf S. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002;105:1650-1655. (Pubitemid 34298607)
14. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol 2003;41:961-965. (Pubitemid 36315537)
15. Ohmori T, Yatomi Y, Nonaka T, Kobayashi Y, Madoiwa S, Mimuro J, Ozaki Y, Sakata Y. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: Involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. J Thromb Haemost 2006;4:1271-1278. (Pubitemid 43756705)
16. Tschoepe D, Roesen P, Kaufmann L, Schauseil S, Kehrel B, Ostermann H, Gries FA. Evidence for abnormal platelet glycoprotein expression in diabetes mellitus. Eur J Clin Invest 1990;20:166-170. (Pubitemid 20126655)
17. Lim HS, Blann AD, Lip GY. Soluble CD40 ligand, soluble P-selectin, interleukin-6, and tissue factor in diabetes mellitus: relationships to cardiovascular disease and risk factor intervention. Circulation 2004;109:2524-2538.
18. Davi G, Catalano I, Averna M, Notarbartolo A, Strano A, Ciabattoni G, Patrono C. Thromboxane biosynthesis and platelet function in type II diabetes mellitus. N Engl J Med 1990;322:1769-1774. (Pubitemid 20194655)
19. Gasparyan AY, Watson T, Lip GY. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol 2008;51:1829-1843. (Pubitemid 351615246)